نتایج جستجو برای: ژن he4

تعداد نتایج: 16408  

2015
Sarikapan Wilailak Karen KL Chan Chi-An Chen Joo-Hyun Nam Kazunori Ochiai Tar-Choon Aw Subathra Sabaratnam Sudarshan Hebbar Jaganathan Sickan Beth A Schodin Chuenkamon Charakorn Walfrido W Sumpaico

OBJECTIVE The purpose of this study was to develop a risk prediction score for distinguishing benign ovarian mass from malignant tumors using CA-125, human epididymis protein 4 (HE4), ultrasound findings, and menopausal status. The risk prediction score was compared to the risk of malignancy index and risk of ovarian malignancy algorithm (ROMA). METHODS This was a prospective, multicenter (n=...

ایزدی, امیر, شاهی, آرزو, مسلمی, الهام,

Introduction: Ovarian cancer is one of the common malignancies within women and the fifth cause of cancer death in women all over the world. Recent developments in Genomics and Proteomics technologies have led to the identification of unknown candidate markers for the diagnosis of ovarian cancer. Human epididymis protein 4 (HE4) has recently been supported to monitor the recurrence or the progr...

ژورنال: طب جنوب 2020
Bolkheir , AmirReza, Cheraghi , Fatemeh, Zargar , Mahvash,

  Background: Given that ovarian cancer symptoms are nonspecific and that appropriate surgical staging and pathological grading are important for the best treatment and prognosis of patients, this study aimed to determine the correlation of preoperative serum levels of CA125 and He4 with staging and grading. Materials and Methods: This cross-sectional study recruited 29 patients with epithelial...

2014
Anita Chudecka-Głaz Aneta Cymbaluk-Płoska Janusz Menkiszak Agnieszka Sompolska-Rzechuła Elżbieta Byra Izabella Rzepka-Górska

BACKGROUND The aim of our study was to evaluate the behaviour of the human epididymis protein 4 (HE4) in the peritoneal fluid encountered in various female genital diseases. METHODS We enrolled 139 patients, 40 with ovarian cancer (group I), 82 with benign diseases (group II), and 17 with other malignant neoplasms (group III). The HE4 tumor marker concentrations were determined in serum, in t...

2012
Viroj Wiwanitkit Karin Sundfeldt

To the editor: The recent publication on ‘HE4, CA-125, and cystic ovarian mass’ is very interesting [1]. Partheen et al. [1] concluded that HE4 did not outperform CA-125. Indeed, the use of two biomarkers might be expected for increased screening ability; however, the problem of the cost should be kept in mind. Incremental analysis on additional cost should be done. Based on the present report,...

2017
Wu Meng Wang Ying Zheng Qichao Li Ping Tang Jie

OBJECTIVES To increase accuracy of the detection and differential diagnosis of the early epithelial ovarian cancer (EOC) with transvaginal contrast-enhanced ultrasonography (TVCEUS) combining serum human epididymisprotein 4 (HE4), and resistance index (RI). Methods: This retrospectively case-control study of 230 patients with ovarian tumors were reviewed at the Department of Gynecology and Obst...

Journal: :Gynecologic oncology 2010
M Robyn Andersen Barbara A Goff Kimberly A Lowe Nathalie Scholler Lindsay Bergan Charles W Drescher Pamela Paley Nicole Urban

BACKGROUND Prior studies suggest that combining the Symptom Index (SI) with a serum HE4 test or a CA125 test may improve prediction of ovarian cancer. However, these three tests have not been evaluated in combination. METHODS A prospective case-control study design including 74 women with ovarian cancer and 137 healthy women was used with logistic regression analysis to evaluate the independe...

2012
Cristina Anton Filomena Marino Carvalho Elci Isabel Oliveira Gustavo ArantesRosaMaciel Edmund Chada Baracat Jesus Paula Carvalho

OBJECTIVE Differentiation between benign and malignant ovarian neoplasms is essential for creating a system for patient referrals. Therefore, the contributions of the tumor markers CA125 and human epididymis protein 4 (HE4) as well as the risk ovarian malignancy algorithm (ROMA) and risk malignancy index (RMI) values were considered individually and in combination to evaluate their utility for ...

2016
KARINA DAHL STEFFENSEN MARIANNE WALDSTRØM IVAN BRANDSLUND BENTE LUND SARAH MEJER SØRENSEN MAX PETZOLD ANDERS JAKOBSEN

The majority of ovarian cancer patients with advanced disease at diagnosis will relapse following primary treatment, with a dismal prognosis. Monitoring the levels of serum markers in patients under follow-up may be essential for the early detection of relapse, and for distinguishing high-risk patients from those with less aggressive disease. The aim of the present study was to investigate the ...

2017
Ran Chen Lunshan Wang Sanhong Liu Xi Chen Yiming Hu Hanshao Liu Haohao Zhang Yuhang Jiang Qi Wang Deji Ye Lingling Li Dandan Liu Xiaorong Pan Lixin Wei Xuemei Li Xiaoren Zhang

Progressive renal fibrosis in chronic kidney disease (CKD) greatly contributes to end-stage renal failure and is associated with high mortality. The identification of renal fibrosis biomarkers for the diagnosis and the monitoring of disease progression in CKD is urgently needed. Whole-transcriptomic analysis of renal tissues in a unilateral ureteral obstruction (UUO) mouse model revealed that t...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید